SUNDERMANN, Bernd,WALZ, Lars,BAASNER, SIlke,NOCKEN, Frank,MEYER, Christoph
申请号：
CL2017001941
公开号：
CL2017001941A1
申请日:
2017.07.28
申请国别(地区):
CL
年份:
2018
代理人:
摘要：
<； p >； The present Invention refers to a Solution, including a pharmaceutically acceptable solution, which comprises dextrin and Starch (has), hidroxialquilWhere the icodextrin is present at a concentration of 1 to 7.5% (W / V) and where that you are present at a concentration of 1 to 15% (W / V).The present Invention also relates to the above solution and pharmaceutically acceptable for use as a drug for use in (e.g.Methods of Prevention of Relapse and / or metastasis formation by administration in a Body Cavity of a subject afflicted with cancer.The present Invention also relates to a kit comprising icodextrin in amounts previously and have heavy and a pharmaceutically acceptable to dissolve them,A device comprising a solution of the present Invention and pharmaceutically acceptable means to manage the same,As well as a pharmaceutically acceptable solution that includes hidroxialquil icodextrin and Starch at a total concentration in the range of 1 to 20% (W / V),Where the ratio in weight of icodextrin in connection with the hidroxialquil Starch is in the range of 0.05: 1 to 5: 1, for use in the Prevention of Relapse and / or metastasis formation by administration in a Body Cavity of a subject afflicted with cancer. <； / p >；USO DE UNA SOLUCIÓN FARMACÉUTICAMENTE ACEPTABLE QUE COMPRENDE 1-7,5 DE ICODEXTRINA Y 1-15 DE HIDROXIALQUIL ALMIDÓN PARA PREPARAR UN MEDICAMENTO ÚTIL PARA LA PREVENCIÓN DE LA FORMACIÓN DE METÁSTASIS YO RECAÍDA POR ADMINISTRACIÓN EN UNA CAVIDAD CORPORAL DE UN SUJETO AFECTADO CON CÁNCER.
